Coya Therapeutics, Inc.
COYA
$4.54
$0.255.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 197,900.00% | -- | -95.22% | 103.39% | -99.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 197,900.00% | -- | -95.22% | 103.39% | -99.97% |
| Cost of Revenue | 155.01% | 31.16% | -19.78% | 66.15% | 20.37% |
| Gross Profit | 49.34% | 129.11% | -206.73% | -64.59% | -144.06% |
| SG&A Expenses | 52.94% | 15.22% | 39.25% | 11.23% | -10.07% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.30% | 23.16% | -1.25% | 42.08% | 2.21% |
| Operating Income | -4.34% | 56.93% | -98.22% | -40.65% | -303.17% |
| Income Before Tax | -56.91% | 47.39% | -110.78% | -44.63% | -282.74% |
| Income Tax Expenses | 100.43% | -- | -- | -- | -199.50% |
| Earnings from Continuing Operations | -95.78% | 47.39% | -110.78% | -44.63% | -330.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.78% | 47.39% | -110.78% | -44.63% | -330.32% |
| EBIT | -4.34% | 56.93% | -98.22% | -40.65% | -303.17% |
| EBITDA | -4.34% | 57.01% | -98.42% | -40.70% | -302.14% |
| EPS Basic | -91.25% | 52.16% | -87.93% | -25.07% | -255.45% |
| Normalized Basic EPS | -5.69% | 63.78% | -87.95% | -25.68% | -212.38% |
| EPS Diluted | -91.25% | 52.16% | -87.93% | -25.07% | -255.45% |
| Normalized Diluted EPS | -5.69% | 63.78% | -87.95% | -25.68% | -212.38% |
| Average Basic Shares Outstanding | 2.36% | 9.93% | 12.13% | 15.65% | 48.23% |
| Average Diluted Shares Outstanding | 2.36% | 9.93% | 12.13% | 15.65% | 48.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |